Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Chase Dukes

Orthopaedic Surgery Helena, MT Medical Doctor

NPI 1518205822 CMS profile 1333322

1645 Vandelay Ave Ste 301, Helena, MT 59601

Open in the dashboard

General payments

$33,811

90 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chase Dukes of Helena, MT is reported in the CMS Open Payments database as having received $33,811 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,607 12
2024 General $340 4
2023 General $2,615 39
2022 General $22,952 12
2021 General $1,546 16
2020 General $4,750 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chase Dukes
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Chase Dukes were reported at $1,607. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Chase Dukes Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $4,750 $312 $75–$1,860 $114
2021 $1,546 $520 $117–$2,495 $132
2022 $22,952 $598 $128–$2,731 $149
2023 $2,615 $461 $128–$2,264 $160
2024 $340 $497 $134–$2,475 $164
2025 $1,607 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Arthrex, Inc. $26,178 28 payments
  2. Zimmer Biomet Holdings, Inc. $2,784 24 payments
  3. Gemini Mountain Medical, LLC $2,400 2 payments
  4. Stryker Corporation $1,008 15 payments
  5. Medacta USA, Inc. $465 8 payments
  6. Smith+Nephew, Inc. $176 3 payments
  7. DePuy Synthes Sales Inc. $143 1 payment
  8. Breg, Inc $135 1 payment
  9. FX Shoulder USA, Inc $134 1 payment
  10. Pacira Pharmaceuticals Incorporated $132 2 payments
  11. Other $255 5 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $20,000 1 payment
  2. Education $6,801 5 payments
  3. Food and Beverage $3,699 70 payments
  4. Travel and Lodging $3,312 14 payments
Products named General payments · program years 2020–2025
  1. Oxford $1,441 10 payments
  2. Oxford-Knees $1,141 9 payments
  3. INSPACE $249 3 payments
  4. TRIATHLON $233 3 payments
  5. ALPHAVENT $198 3 payments
  6. GMK SPHERE $196 2 payments
  7. GMK Sphere Revision System $179 2 payments
  8. ACCOLADE $150 2 payments
  9. Breg VPULSE, PlasmaFlow, PolarCareWave $135 1 payment
  10. Iovera $132 2 payments
  11. Other $1,477 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

101

Median for Orthopedic Surgery: 203

Drug cost

$287

Median for Orthopedic Surgery: $1,433

Branded share of claims

10.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naproxen Generic 27 $87
Dexamethasone Generic 33 $76
Ondansetron Odt Ondansetron Brand 11 $74
Cephalexin Generic 13 $33
Meloxicam Generic 17 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$47,027

Of which drugs: $977

Medicare patients

172

Average age 72

Services billed

820

100 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 59%
Ischemic heart disease 19%
Depression 17%
COPD 16%
Osteoporosis 15%
Diabetes 14%
Chronic kidney disease 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 208 $158
Injection, ketorolac tromethamine, per 15 mg J1885 Office 28 82 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record